Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Initial Release Of Essential Drug List Benefits Companies With Unique Products

This article was originally published in PharmAsia News

Executive Summary

On the recently issued essential drug list, analysts point out that most of the unique products on the catalogue are produced by traditional Chinese medicine companies, while a few are chemical drugs. TCM firms with unique products include Guizhou Tongjitang Pharmaceutical, Yunnan Baiyao Group, Sanjiu Medical and Pharmaceutical, Guangzhou Pharmaceutical Company and Tianjin Zhongxin Pharmaceutical Group. Unique chemical products include fentanyl and a fentanyl patch made by Wuhan Humanwell Hi-tech Industry and Changzhou Siyao Pharm, and Xinhua Pharmaceutical's sodium stibogluconate. Observers believe that national and regional pharmaceutical distributors such as Sinopharm Medicine Holdings and Shanghai Pharmaceutical will also benefit from the reform. Analysts lean toward larger drug companies with flexibility as possible investment choices. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel